AR058983A1 - Metodos y composiciones para el tratamiento de enfermedades alergicas - Google Patents

Metodos y composiciones para el tratamiento de enfermedades alergicas

Info

Publication number
AR058983A1
AR058983A1 ARP070100117A ARP070100117A AR058983A1 AR 058983 A1 AR058983 A1 AR 058983A1 AR P070100117 A ARP070100117 A AR P070100117A AR P070100117 A ARP070100117 A AR P070100117A AR 058983 A1 AR058983 A1 AR 058983A1
Authority
AR
Argentina
Prior art keywords
methods
compositions
treatment
allergic diseases
antibodies
Prior art date
Application number
ARP070100117A
Other languages
English (en)
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of AR058983A1 publication Critical patent/AR058983A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Anticuerpos que reconocen y antagonizan específicamente al receptor de TSLP humano, y métodos para emplear estos anticuerpos con el fin de tratar o disminuir las enfermedades o los trastornos mediados por la senalizacion de TSLP. Reivindicacion 1: Un anticuerpo aislado, o una porcion de enlace de antígeno del mismo, que comprende una secuencia de region variable de cadena pesada de la SEQ ID N°:5.
ARP070100117A 2006-01-13 2007-01-11 Metodos y composiciones para el tratamiento de enfermedades alergicas AR058983A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75962506P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
AR058983A1 true AR058983A1 (es) 2008-03-05

Family

ID=38541770

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100117A AR058983A1 (es) 2006-01-13 2007-01-11 Metodos y composiciones para el tratamiento de enfermedades alergicas

Country Status (13)

Country Link
US (2) US8097705B2 (es)
EP (2) EP1981912A2 (es)
JP (1) JP5258578B2 (es)
KR (1) KR101383472B1 (es)
CN (1) CN101370831B (es)
AR (1) AR058983A1 (es)
AU (1) AU2007230868B2 (es)
BR (1) BRPI0706530A2 (es)
CA (1) CA2635599C (es)
PE (1) PE20081186A1 (es)
RU (1) RU2486202C2 (es)
TW (1) TWI401261B (es)
WO (1) WO2007112146A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
PT2077279E (pt) * 2000-06-28 2012-09-14 Amgen Inc Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
PT1417231E (pt) 2001-07-23 2013-07-29 Immunex Corp Linfopoietina estromal tímica humana modificada
KR20100034015A (ko) * 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CA2713935C (en) 2008-02-07 2016-11-01 Schering Corporation Engineered anti-tslpr antibodies
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
KR101725170B1 (ko) * 2009-05-06 2017-04-10 바이오테스트 아게 Ｃｄ１３８을 표적으로 하는 면역접합체의 용도
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
CN104098696A (zh) * 2013-04-07 2014-10-15 中美华世通生物医药科技（武汉）有限公司 一种抗血管内皮生长因子的单克隆抗体
MY177098A (en) * 2013-08-09 2020-09-05 Astellas Pharma Inc Novel anti-human tslp receptor antibody
CN104804087A (zh) * 2014-01-26 2015-07-29 中美华世通生物医药科技（武汉）有限公司 一种抗血管内皮生长因子的单克隆抗体16-3
CN104804088A (zh) * 2014-01-26 2015-07-29 中美华世通生物医药科技（武汉）有限公司 一种抗vegf的单克隆抗体
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
AU2016318158B2 (en) * 2015-09-04 2022-09-15 Health Research, Inc. Anti-survivin antibodies for cancer therapy
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
LT3347377T (lt) * 2015-09-09 2021-05-25 Novartis Ag Užkrūčio liaukos stromos limfopoetiną (tslp) rišantys antikūnai ir antikūnų panaudojimo būdai
SG11201805123XA (en) 2015-12-18 2018-07-30 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
WO2017146011A1 (ja) * 2016-02-22 2017-08-31 国立大学法人 千葉大学 アレルギー性鼻炎の診断用バイオマーカー
CN110997939A (zh) * 2017-08-16 2020-04-10 免疫医疗有限责任公司 用于治疗特应性皮炎的组合物和方法以及治疗选择
CN109988759A (zh) * 2017-12-29 2019-07-09 上海细胞治疗研究院 一种在t细胞中具有高转录活性的嵌合启动子
CN111196850B (zh) * 2020-02-07 2020-10-30 北京汇智和源生物技术有限公司 人胸腺基质淋巴细胞生成素单克隆抗体及其应用
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
WO2023028612A2 (en) 2021-08-27 2023-03-02 Board Of Regents, The University Of Texas System Anti-tslpr (crlf2) antibodies
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334255D1 (de) * 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
DE69936105T3 (de) * 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
PT2077279E (pt) * 2000-06-28 2012-09-14 Amgen Inc Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
KR101194446B1 (ko) * 2004-04-29 2012-10-24 오쓰까 세이야꾸 가부시키가이샤 당단백 ｖｉ에 특이적인 항체 및 그의 제조방법
CA2577631A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation

Also Published As

Publication number Publication date
AU2007230868B2 (en) 2012-02-02
KR101383472B1 (ko) 2014-04-08
RU2008132968A (ru) 2010-02-20
EP2287196A2 (en) 2011-02-23
EP1981912A2 (en) 2008-10-22
US20120027756A1 (en) 2012-02-02
CN101370831A (zh) 2009-02-18
TW200736275A (en) 2007-10-01
EP2287196A3 (en) 2011-05-04
BRPI0706530A2 (pt) 2011-03-29
WO2007112146A3 (en) 2008-06-05
US8097705B2 (en) 2012-01-17
JP5258578B2 (ja) 2013-08-07
US20090286312A1 (en) 2009-11-19
JP2009523426A (ja) 2009-06-25
CA2635599C (en) 2014-06-17
CA2635599A1 (en) 2007-10-04
RU2486202C2 (ru) 2013-06-27
TWI401261B (zh) 2013-07-11
KR20080090418A (ko) 2008-10-08
CN101370831B (zh) 2013-06-19
PE20081186A1 (es) 2008-09-24
AU2007230868A1 (en) 2007-10-04
WO2007112146A2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
AR058983A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
AR067045A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
CY1120108T1 (el) Αντισωματα που προσδενουν il-4 και/ή il-13 και οι χρησεις τους
CY1120471T1 (el) Αντισωματα κατα του cd70
AR105490A2 (es) Generación y perfilado de anticuerpos terapéuticos derivados de hucal gold totalmente humanos específicos para cd38 humano
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
PE20210115A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
AR083747A1 (es) Anticuerpos anti-il-23
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
PE20120429A1 (es) Proteinas de enlace de miostatina
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
PE20121361A1 (es) Antagonistas de pcsk9
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
PE20181176A1 (es) Composiciones biofarmaceuticas
CR20110152A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal